Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$319.58 USD
+60.24 (23.23%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $318.00 -1.58 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
MDGL 319.58 +60.24(23.23%)
Will MDGL be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MDGL
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
Other News for MDGL
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
Madrigal, 89Bio jump after Novo's semaglutide shows promise in MASH
Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL), Organon (OGN) and Haleon PLC Sponsored ADR (HLN)
Evercore ISI Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)